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Abstract 
Short communication on TALDO1, with data on 
DNA/RNA, on the protein encoded and where the gene 
is implicated. 
Identity 
Other names: TAL, TAL-H, TALDOR, TALH 
HGNC (Hugo): TALDO1 
Location: 11p15.5 
DNA/RNA 
Note 
Starts at 747432 bp from pter and ends at 765024 bp 
from pter according to hg19-Feb_2009. 
Size: 17593 bases; Orientation: TALDO1 is on the plus 
strand. 
Description 
Exons 2 and 3 of TALDO1 contain retrotransposable 
elements (Banki et al., 1994). 
Transcription 
TALDO1 has 8 exons and its mRNA is composed of 
1319 bp. 
Pseudogene 
TALDO1P1 (Transaldolase 1 pseudogene 1). 
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The 3-dimensional structure of transaldolase from Thorell et al., 2000. Image downloaded from http://www.ebi.ac.uk.  
 
 
 
From blast of reference proteins (Refseq) against human Transaldolase (NP_006746.1). 
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Protein 
Description 
Transaldolase (TAL) is a 337 amino acid protein in the 
non-oxidative phase of the pentose phosphate pathway 
(PPP) with a predicted mass of 37.55kDa. TAL has an 
α/β barrel and that includes lysine 142 which is 
responsible for generating the Schiff base intermediate 
during sugar phosphate metabolism (Thorell et al.,200).  
A mass spectrometry based investigation of the 
acetylome identified TAL acetylation at lysines 286, 
269, 321, 219 (Choudhary et al., 2009).  
It has also been proposed that TAL activity may be 
affected by phosphorylation (Lachaise et al., 2001). 
Expression 
TALDO1 is ubiquitously expressed, except in 
erythrocytes. 
Localisation 
Cytosol and nucleus (Colombo et al., 1997). 
Function 
The reversible reaction carried out by TAL is: erythros-
4-phosphate+fructose-6-phophateglyceraldehydes-3-
phosphate+sedoheptulose-7-phosphate. TAL has been 
proposed as the rate limiting enzyme in the non-
oxidative PPP (Banki et al., 1996; Heinrich et al., 1976; 
Perl, 2007; Wood, 1985). 
Homology 
Using the blastp function within Homo sapiens, the 
only protein to share homology within humans (a 
paralog) was sorting nexin 32 (SNX32) with an identity 
of 36%. 
Mutations 
Germinal 
Homozygous deletion of Serine 171 due to the loss of 
3bp in the TALDO1 sequence results in liver cirrhosis 
and subsequent carcinogenesis. 
Implicated in 
Hepatocellular carcinoma 
Cytogenetics 
Deletion of nucleotides 512-514 in TALDO1 resulted 
in the loss of serine 171 in the TAL protein and 
subsequent TAL deficiency (Verhoeven et al., 2001; 
Valayannopoulos et al., 2006). TAL  
deficiency results in the accumulation of 
sedoheptulose-7-phosphate and polyols. Further studies 
into TAL deficiency determined that the deletion of 
S171 resulted in a complete loss of enzymatic activity 
and rapid degradation in the proteasome (Grossman et 
al., 2004). Missense mutations at arginine 192, in 
which the arginine is mutated to either a histidine or 
cysteine, also results in loss of TAL activity and liver 
damage in patients (Verhoeven et al., 2005; Wamelink 
at al., 2008). In addition to liver damage, renal and 
cardiac complications are also present in these patients 
(Verhoeven et al., 2001; Valayannopoulos et al., 2006; 
Verhoeven et al., 2005; Wamelink et al., 2008). 
In a mouse model of TAL deficiency, sperm 
dysmotility and subsequent male infertility are present 
(Perl et al., 2006). Furthermore, TAL deficiency results 
in the development of hepatosteatosis, cirrhosis, and 
hepatocellular carcinoma in both homozygous TAL 
knockouts and heterozygous mice relative to C57Bl/6 
wild type mice (Hanczko et al., 2009).  
The pathogenic mechanism of liver damage in TAL 
deficiency is linked to depletion of NADPH, oxidative 
stress, and mitochondrial dysfunction (Perl et al., 
2011).  
In TAL deficiency, it has been proposed that oxidative 
stress is exacerbated by increased aldose reductase 
activity which generates polyols and depletes NADPH 
(Perl et al., 2011). Low NADPH diminishes the cells 
ability to regulate cellular redox and polyols can induce 
proliferation through JNK/c-Jun (Perl et al., 2011). 
Thus, TAL deficiency and insufficiency predispose to 
oxidative stress which promotes liver damage, 
increased proliferation, and hepatocellular carcinoma. 
Squamous cell carcinoma of the head 
and neck 
Cytogenetics 
3 SNPs in the TALDO1 gene have been associated 
with different squamous cell carcinoma of the head and 
neck risk.  
The conversion of cytosine to either guanine or 
thymine at 490bp upstream of the origin of replication 
(rs10794338) was protective against tumorigenesis 
(Basta et al., 2008).  
In contrast, the mutation of thymine to adenine at 
position 1874 (rs3901233) and adenine to cytosine at 
position 2187 (rs4963163) increase the risk of 
squamous cell cancer of the head and neck (Basta et al., 
2008). 
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From blastp of NP_006746.1 against all non-redundant protein sequences. 
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